Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase …
SH Hsiao, HE Liu, HL Lee, CL Lin, WY Chen, ZH Wu… - PLoS …, 2013 - journals.plos.org
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in …
Post-progression survival after EGFR-TKI for advanced non-small cell lung cancer harboring EGFR mutations
Background Non-small cell lung cancer (NSCLC) patients that harbor epidermal growth
factor receptor (EGFR) mutations benefit from receiving an EGFR-tyrosine kinase inhibitor …
factor receptor (EGFR) mutations benefit from receiving an EGFR-tyrosine kinase inhibitor …
Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with …
B Chua, EH Tan, DWT Lim, MK Ang… - Annals of …, 2018 - annalsofoncology.org
Background: Treatment options for EGFR mutant advanced/metastatic NSCLC patients
continue to evolve with the development of 2nd and 3rd generation EGFR TKIs. We aim to …
continue to evolve with the development of 2nd and 3rd generation EGFR TKIs. We aim to …
[PDF][PDF] Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors …
Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine …
YM Chen, CH Lai, HC Chang, TY Chao, CC Tseng… - Lung cancer, 2016 - Elsevier
Objectives In daily practice, some patients with certain clinical characteristics may have
better responses to the administration of epidermal growth factor receptor (EGFR)—tyrosine …
better responses to the administration of epidermal growth factor receptor (EGFR)—tyrosine …
EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy
YH Kim, K Masago, Y Togashi… - Oncology …, 2011 - spandidos-publications.com
Somatic mutations of epidermal growth factor receptor (EGFR) are the strongest predictive
markers for the response to EGFR-tyrosine kinase inhibitors (TKIs). Patients with EGFR …
markers for the response to EGFR-tyrosine kinase inhibitors (TKIs). Patients with EGFR …
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
JY Lee, SH Lim, M Kim, S Kim, HA Jung… - Cancer chemotherapy …, 2014 - Springer
Abstract Background Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
[HTML][HTML] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line …
E Bria, M Milella, F Cuppone, S Novello, A Ceribelli… - Annals of oncology, 2011 - Elsevier
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives
R Costanzo, A Montanino, M Di Maio… - Expert Review of …, 2013 - Taylor & Francis
The identification of activating mutations in the tyrosine kinase domain of the EGF receptor
(EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic …
(EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic …
[HTML][HTML] Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation–positive non–small-cell lung cancer treated …
M Takeda, I Okamoto, K Nakagawa - Journal of Thoracic Oncology, 2014 - Elsevier
Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …
相关搜索
- egfr tyrosine kinase inhibitors
- egfr mutation lung cancer
- egfr mutation survival outcome
- egfr mutations nsclc patients
- survival outcome lung cancer
- egfr tkis clinical outcome
- egfr tyrosine clinical parameters
- clinical parameters kinase inhibitors
- egfr mutation stratification factor
- egfr mutation tumor response
- tumor response lung cancer
- egfr mutations meta analysis
- egfr mutation shrinkage pattern
- shrinkage pattern lung cancer
- tumor response survival outcome
- meta analysis nsclc patients